-
Income Statement
-
Balance Sheet
-
Cashflow Statement
-
Profitability
-
Ratios
AbbVie Income Statement
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Revenue |
|
$45.80B | $56.20B | $58.05B | $54.32B |
| Cost of Revenue |
|
$15.39B | $17.45B | $17.41B | $20.42B |
| Gross Profit |
|
$30.42B | $38.75B | $40.64B | $33.90B |
| Research & Development |
|
$6.56B | $7.08B | $6.51B | $8.45B |
| Selling,General & Administrative |
|
$11.30B | $12.35B | $15.26B | $12.87B |
| Operating Expense |
|
$17.86B | $19.87B | $21.83B | $21.15B |
| Operating Income |
|
$11.36B | $17.92B | $18.12B | $12.76B |
| Net Income |
|
$4.62B | $11.54B | $11.84B | $4.86B |
AbbVie Balance Sheet
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Cash and Cash Equivalents |
|
$8.48B | $9.83B | $9.23B | $12.82B |
| Inventories |
|
$3.31B | $3.13B | $3.58B | $4.10B |
| Total Current Assets |
|
$24.17B | $27.93B | $28.46B | $33.00B |
| Property,Plant and Equipment |
|
$5.25B | $5.11B | $4.94B | $4.99B |
| Goodwill |
|
$33.12B | $32.38B | $32.16B | $32.29B |
| Total Assets |
|
$150.57B | $146.53B | $138.81B | $134.71B |
| Total Liabilities |
|
$137.47B | $131.09B | $121.52B | $124.31B |
| Retained Earnings |
|
$1.06B | $3.13B | $4.78B | -$1.00B |
| Total Shareholder Equity |
|
$13.08B | $15.41B | $17.25B | $10.36B |
| Common Stock |
|
$18.00M | $18.00M | $18.00M | $18.00M |
AbbVie Cash flow
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Depreciation & Amortization |
|
$6.47B | $8.52B | $8.47B | $8.70B |
| Dividends Payout |
|
-$7.72B | -$9.26B | -$10.04B | -$10.54B |
| Capital Expenditures (Capex) |
|
-$798.00M | -$787.00M | -$695.00M | -$777.00M |
| Free Cash Flow (FCF) |
|
$16.79B | $21.99B | $24.25B | $22.06B |
AbbVie Profitability
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gross Profit |
|
$30.42B | $38.75B | $40.64B | $33.90B |
| Gross Profit Margin (%) |
|
66.41% | 68.96% | 70.00% | 62.42% |
| Operating Income |
|
$11.36B | $17.92B | $18.12B | $12.76B |
| Operating Income Margin (%) |
|
24.81% | 31.89% | 31.21% | 23.49% |
| Net Income |
|
$4.62B | $11.54B | $11.84B | $4.86B |
| Net Income Margin (%) |
|
10.08% | 20.54% | 20.39% | 8.95% |
| EBITDA |
|
$21.15B | $28.28B | $31.42B | $17.31B |
| EBITDA Margin (%) |
|
15.17% | 47.06% | 45.79% | 31.86% |
AbbVie Ratios
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Return on Equity (ROE) |
|
35.30% | 74.91% | 68.60% | 46.94% |
| Return on Assets (ROA) |
|
3.07% | 7.88% | 8.53% | 3.61% |
| Debt to Equity |
|
658.12% | 497.69% | 366.70% | 573.21% |
| Debt to total asset |
|
57.16% | 52.33% | 45.58% | 44.08% |
| Enterprise value to revenue |
|
5.59 | 5.46 | 5.86 | 5.90 |
| Enterprise value to EBITDA |
|
12.12 | 10.84 | 10.83 | 18.52 |
| Enterprise value |
|
$256.23B | $306.60B | $340.28B | $320.56B |
| Cash to Debt |
|
20.44% | 29.70% | 39.42% | 38.46% |
| Tax Rate (%) |
|
36.02% | 11.09% | 12.11% | 22.03% |
| Payout Ratio |
|
167.16% | 80.24% | 84.85% | 216.72% |
Related company
